혈액종양내과
이소흔
진료분야 악성 및 양성 혈액질환 (림프종, 다발골수종 등), 소화기암 (간·담도·췌장암, 대장암)
진료예약모바일로 확인하실 경우 표를 좌우로 움직여 내용을 확인 하실 수 있습니다.
| 0000 00 |
|---|
| 오전 |
| 오후 |
진료과 사정에 따라 진료 일정이 변경될 수 있습니다. 자세한 일정은 진료과로 문의 바랍니다.
- 외래진료
- 국내 학회
- 국외 학회
- 강의
- 휴가
- 기타
| 0000 00 |
|---|
| 오전 |
| 오후 |
진료과 사정에 따라 진료 일정이 변경될 수 있습니다. 자세한 일정은 진료과로 문의 바랍니다.
- 외래진료
- 국내 학회
- 국외 학회
- 강의
- 휴가
- 기타
- 논문 더보기
-
- Lee SH, Park I, Yoon S, Lee JL. Efficacy and safety of lenvatinib plus everolimus in metastatic renal cell carcinoma after immune checkpoint and VEGFR tyrosine kinase inhibitors treatment. Cancer Research and Treatment. 2025.
- Lee SH, Cheon J, Kim I, Kim KP, Ryoo BY, Jeong JH, Kang MJ, Kang BW, Ryu H, Lee JS, Yoo C. Serum 25-hydroxyvitamin D levels and survival outcomes in advanced biliary tract cancer: Results from the NIFTY trial. Cancer Medicine. 2025;14(1):e70560.
- Iavarone M, Alimenti E, Tada T, Shimose S, Suda G, Yoo C, Lee SH, et al. Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma receiving lenvatinib. Liver Cancer. 2024;13(2):215-226.
- Lee SH, Jeong H, Kim DH, Jang SJ, Kim SW, Yoon S, Lee DH. Comparison of clinicopathogenomic features and treatment outcomes of EGFR and HER2 exon 20 insertion mutations in non-small cell lung cancer: A single-institution experience. Cancer Research and Treatment. 2024;56(3):774-784.
- Lee SH, Hwang DW, Yoo C, Kim KP, Kang S, Jeong JH, Oh D, Song TJ, Lee SS, Park DH, Seo DW, Park JH, Song KB, Lee JH, Lee W, Park Y, Kwak BJ, Chang HM, Ryoo BY, Kim SC. Survival benefit of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma who underwent surgery following neoadjuvant FOLFIRINOX. Cancer Research and Treatment. 2023;55(3):956-968.
- Kang S, Yoo C, Lee SH, Oh D, Song TJ, Lee SS, Jeong JH, Park DH, Seo DW, Park JH, Hwang DW, Song KB, Lee JH, Lee W, Kwak BJ, Hong S, Chang HM, Ryoo BY, Kim KP, Kim SC. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Therapeutic Advances in Medical Oncology. 2022;14:17588359221097190.
- Kang S, Lee SH, Lee HJ, Jeong H, Jeong JH, Kim JE, Ahn JH, Jung KH, Gong G, Kim HH, Lee S, Lee J, Kim SB. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy. European Journal of Cancer. 2022;176:30-40.
서울특별시 종로구 새문안로 29 (03181) 강북삼성병원
대표전화 1599-8114
팩스번호 02-2001-2117
사업자번호 110-82-02349
Copyright(c) by Kangbuk Samsung hospital. all right reserved.